Results 31 to 40 of about 11,960 (207)

Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. [PDF]

, 2006
OBJECTIVES: To compare the efficacy and safety of artemisinin combination therapies for the treatment of uncomplicated falciparum malaria in Uganda. DESIGN: Randomized single-blind controlled trial.
Staedke Sarah G, Rosenthal, Philip J, Yeka, Adoke, Banek, Kristin, Yeka Adoke, Dorsey, Grant, Staedke, Sarah G, Bakyaita Nathan, Dorsey Grant, Banek Kristin, Bukirwa, Hasifa, Talisuna Ambrose, Rosenthal Philip J, Talisuna, Ambrose, Rwakimari, John Bosco, Kamya Moses R, Kamya, Moses R, Bukirwa Hasifa, Wabwire-Mangen Fred, Bakyaita, Nathan, Wabwire-Mangen, Fred, Rwakimari John Bosco   +21 more
core   +1 more source

Formulation, process development and evaluation of artemether and lumefantrine soft gelatin capsule

Journal of Pharmacy and Bioallied Sciences, 2012
Artemether and Lumefantrine capsules are indicated for the treatment of P. falciparum malaria cases resistant to both chloroquine and sulphadoxine, pyrimethamine combination. Both artemether and lumefantrine act as blood schizontocides.
A Patel, A Lodha, J Chaudhuri, P Jadia, T Joshi, J Dalal   +5 more
doaj   +1 more source

Electrocardiographic safety evaluation of extended artemether-lumefantrine treatment in patients with uncomplicated Plasmodium falciparum malaria in Bagamoyo District, Tanzania

Malaria Journal, 2020
Background Extended artemisinin-based combination therapy (ACT) for treatment of uncomplicated Plasmodium falciparum malaria with already existing drug regimens, such as artemether-lumefantrine, might be effective in tackling the emerging ACT resistance.
Lwidiko E. Mhamilawa, Sven Wikström, Bruno P. Mmbando, Billy Ngasala, Andreas Mårtensson   +4 more
doaj   +1 more source

Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania. [PDF]

, 2012
A follow-up study was conducted to determine the magnitude of and factors related to adherence to artemether/lumefantrine (ALu) treatment in rural settings in Tanzania.
Zul Premji, Simba, Daudi O, Petzold, Max, Gustafsson, Lars L, Simba, D.O., Daudi O. Simba, Tomson, G., Mahindi, M., Goran Tomson, Lars L. Gustafsson, Kakoko, Deodatus, Max Petzold, Deodatus Kakoko, Margarita Mahindi, Kakoko, D., Petzold, M., Tomson, Goran, Gustafsson, L.L., Mahindi, Margarita, Premji, Zul   +19 more
core   +1 more source

Genome‐Guided Discovery of Antimalarial 4‐Amino‐2,4‐Pentadienoate‐Containing Cyclolipodepsipeptides

Angewandte Chemie, Volume 138, Issue 18, 27 April 2026.
Halogenated and glycosylated 4‐amino‐2,4‐pentadienoate‐containing cyclolipodepsipeptides (APD‐CLDs) exhibit potent antiplasmodial activity (IC50 = 25–161 nM) against drug‐sensitive and resistant Plasmodium falciparum strains. ABSTRACT 4‐Amino‐2,4‐pentadienoate‐containing cyclolipodepsipeptides (APD‐CLDs) represent a structurally distinctive family of ...
Hartono Candra, Xue‐Jiao Wang, Ka Diam Go, Li Feng, Miaomiao Cai, Guang‐Lei Ma, Clarissa Widyantoro, Lik Tong Tan, Zbynek Bozdech, Zhe Wang, Zhao‐Xun Liang   +10 more
wiley   +2 more sources

A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya

Malaria Journal, 2008
Background Artemether/lumefantrine (AL) has been adopted as the treatment of choice for uncomplicated malaria in Kenya and other countries in the region.
Akhwale Willis S, Obonyo Charles O, Juma Elizabeth A, Ogutu Bernhards R   +3 more
doaj   +1 more source

Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. [PDF]

, 2014
Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) and P.
Kamugisha, Erasmus, Piola, Patrice, Faucher, Jean-François, El-Sayed, Badria, Houzé, Sandrine, Somé, A Fabrice, Sutherland, Colin, Checchi, Francesco, Plowe, Christopher, V, Sutherland, Colin J, Otienoburu, Sabina Dahlström, Berens-Riha, Nicole, Grivoyannis, Anastasia, Davis, Timothy ME, Björkman, Anders, Asaq Molecular Marker Study Group, Rosenthal, Philip, Eyase, Frederick, Malmberg, Maja, Kariuki, Simon, Mårtensson, Andreas,, Hamour, Sally, Ogutu, Bernhards, Davis, Timothy, Wong, Rina, Sibley, Carol Hopkins, Gadalla, Nahla B, Ngasala, Billy, Ménard, Didier, Oguike, Mary, Venkatesan, Meera, Arze, Cesar, Djimdé, Abdoulaye A, Baliraine, Frederick N, Fröberg, Gabrielle, Ursing, Johan, LeBras, Jacques, Desai, Meghna, Mårtensson, Andreas, Ouédraogo, Jean-Bosco, El-Sayed, Badria B, Mwai, Leah, Thwing, Julie, Kironde, Fred, Djimde, Abdoulaye, Price, Ric, Dorsey, Grant, Johnson, Jacob, Guérin, Philippe, Somé, A. Fabrice, Oguike, Alexis Nzila Mary, LeBras, Poul-Erik Kofoed Jacques, Moriera, Clarissa, Kiechel, Jean-René, Kofoed, Poul-Erik, Dahal, Prabin, Nsanzabana, Christian, Nzila, Alexis, Wong, Rina PM, Rosenthal, Philip J, Ademowo, George, Falade, Catherine, Nsobya, Samuel L, Schramm, Birgit, Zongo, Issaka, Gadalla, Nahla, Wong, Rina P M, Plowe, Christopher V, Eshetu, Teferi, Davis, Timothy M E, Dhorda, Meghna Desai Mehul, Plowe, Christopher,, Rombo, Lars,, Dhorda, Mehul, Stepniewska, Kasia, Adam, Ishag, Price, Ric N, Borrmann, Steffen, Nosten, Francois, Rombo, Lars, Baliraine, Frederick, Zeynudin, Ahmed, Nsobya, Samuel   +82 more
core   +1 more source

Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change

The Pan African Medical Journal, 2020
INTRODUCTION: Artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) are the first line therapy of uncomplicated malaria in Burkina Faso. We assessed the treatment efficacy, tolerability of these drugs 11 years following its adoption as first ...
Issaka Zongo, Yves Daniel Compaoré, Frédéric Nikiéma, Moussa Zongo, Nouhoun Barry, Fabrice Anyirékun Somé, Naomie Kaboré, Jean Bosco Ouédraogo   +7 more
doaj   +1 more source

Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. [PDF]

, 2010
\ud \ud Controlled clinical trials have shown that a six-dose regimen of artemether-lumefantrine (AL) therapy for uncomplicated Plasmodium falciparum malaria results in cure rates >95% with good tolerability.
Abdunoor M Kabanywanyi, Nathan Mulure, King'eng'ena, Said, Kabanywanyi Abdunoor M, Mulure, Nathan, Christian Lengeler, Prudensiana Kasim, Schlienger, Raymond, Raymond Schlienger, King'eng'ena S.,, Lengeler Christian, Blaise Genton, Mulure, N., Lengeler, C., Genton, Blaise, Lengeler, Christian, Genton Blaise, Kasim Prudensiana, Kasim, Prudensiana, Kabanywanyi, A. M., King'eng'ena Said, Schlienger Raymond, Mulure Nathan, Kabanywanyi, Abdunoor M, Schlienger, R., Said King'eng'ena, Genton, B., Kasim, P.   +27 more
core   +1 more source

Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial

Malaria Journal, 2012
Background Children are most vulnerable to malaria. A pyronaridine-artesunate pediatric granule formulation is being developed for the treatment of uncomplicated Plasmodium falciparum malaria. Methods This phase III, multi-center, comparative, open-label,
Kayentao Kassoum, Doumbo Ogobara K, Pénali Louis K, Offianan André T, Bhatt Kirana M, Kimani Joshua, Tshefu Antoinette K, Kokolomami Jack HT, Ramharter Michael, de Salazar Pablo Martinez, Tiono Alfred B, Ouédraogo Alphonse, Bustos Maria Dorina G, Quicho Frederick, Borghini-Fuhrer Isabelle, Duparc Stephan, Shin Chang-Sik, Fleckenstein Lawrence   +17 more
doaj   +1 more source